Iterion Therapeutics

Executive Summary

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing tegavivint, a first-in-class small molecule that selectively degrades nuclear β-catenin to inhibit oncogenic Wnt/β-catenin signaling. This pathway is aberrantly activated in multiple cancers, including advanced hepatocellular carcinoma (HCC), where current therapies are limited. Tegavivint has demonstrated preclinical efficacy and is currently in Phase 1 clinical trials for HCC, with a focus on patients refractory to standard treatments. The drug's unique mechanism of targeting β-catenin degradation offers potential for durable responses and combination opportunities. Iterion's strategy is to address high unmet medical need in Wnt-driven tumors, initially in HCC and expanding to other indications. The company is privately funded and based in Houston, Texas, with a lean operational model to advance its pipeline efficiently. While early-stage, the novelty of the target and the specificity of the approach position Iterion as a compelling player in the oncology space, subject to successful clinical validation.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Data Readout for Tegavivint in Advanced HCC60% success
• Q2 2027Initiation of Phase 2 Study in HCC or Expansion Indication40% success